A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

MLA

Mok, Tony, et al. “A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015).” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 9, no. 6, June 2014, pp. 848–55. EBSCOhost, https://doi.org/10.1097/JTO.0000000000000160.

APA

Mok, T., Gorbunova, V., Juhasz, E., Szima, B., Burdaeva, O., Orlov, S., Yu, C.-J., Archer, V., Hilton, M., Delmar, P., Pallaud, C., & Reck, M. (2014). A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 9(6), 848–855. https://doi.org/10.1097/JTO.0000000000000160

Chicago

Mok, Tony, Vera Gorbunova, Erzsebet Juhasz, Barna Szima, Olga Burdaeva, Sergey Orlov, Chong-Jen Yu, et al. 2014. “A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015).” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 9 (6): 848–55. doi:10.1097/JTO.0000000000000160.